Inclusion Criteria:~* consent to receive disclosure of their risk estimates to develop clinical symptoms of AD
based on their APOE genotype and, if Heterozygotes, evidence of elevated brain amyloid.~* Male or female, age
60 to 75 years inclusive. Females must be considered post-menopausal and not of child bearing potential~*
Cognitively unimpaired as evaluated by memory tests performed at screening.~* Participant's willingness to have
a study partner.~* Carrier of at least one APOE4 gene if Heterozygotes, elevated brain amyloid (as measured by
CSF Abeta or amyloid PET imaging).~
